HeartBeam has highlighted data from the study using HeartBeam AI with vectorcardiography (VCG) vs single-lead ECGs to detect atrial flutter at the European Heart Rhythm Association (EHRA) conference
The study demonstrated an improvement of 28% in identifying atrial flutter cases with a sensitivity of 91.0% with VCG vs 71.2% with single-lead ECG. It showed a specificity of 98.7% vs 96.9% in the identification of individuals with or without atrial flutter
The company’s 3D VECG technology, for remote cardiac monitoring, works by capturing heart signals through X, Y & Z projections to synthesize 12-lead ECG. Its 1st application will be in HeartBeam AIMIGo which is currently under the US FDA’s review
Ref: HeartBeam | Image: HeartBeam
Related News:- HeartBeam Enrolls First Patients for the Clinical Evaluation of AIMIGo System for Arrhythmia Detection
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
